Australian radiopharmaceutical developer Clarity Pharmaceuticals has completed recruitment for a PET study of its theranostic agent with copper-based radioisotopes for treating patients with prostate cancer.
Researchers have enrolled 30 participants who have confirmed prostate cancer and have been scheduled for radical prostatectomy. The individuals have been enrolled in the trial across multiple clinical sites in Australia.
In this trial, Clarity is investigating the diagnostic efficacy of targeted copper-67 (Cu-67) using its SAR-bisPSMA, which targets prostate-specific membrane antigen (PSMA) expressed by prostate tumors, to the prostate cancer tissue samples. Also, it will explore how the images compare with gallium-68 (Ga-68) PSMA-11, which is already approved for use in Australia and the U.S.
